10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)

Wed, May 7, 11:42 AM (15 days ago)

**Lantheus Holdings, Inc. (LNTH) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $372.8M, up 0.8% YoY. - **Net Income:** $72.9M, down 44.3% YoY. - **EPS:** $1.06 (basic), $1.02 (diluted). - **Cash Flow from Operations:** $107.6M. - **Cash & Equivalents:** $938.5M. **Key Metrics:** - **Gross Profit Margin:** 63.8%, down from 66.4% YoY. - **Operating Income Margin:** 27.4%, down from 28.8% YoY. - **R&D Expenses:** $36.3M, down 24.4% YoY. - **SG&A Expenses:** $103.1M, up 18.6% YoY. **Quarterly Performance:** - **Revenue Growth:** Driven by DEFINITY sales and milestone achievements. - **Profit Margins:** Decreased due to higher costs and lower PYLARIFY net sales price. - **Cash Flow:** Positive, with significant investments in acquisitions and R&D. **Trends & Uncertainties:** - **PYLARIFY:** Continued growth but faces competition and potential generic entrants. - **DEFINITY:** Strong sales and market share, with expansion into pediatric use. - **Acquisitions:** Strategic deals to expand pipeline and capabilities, with potential milestone payments. - **Regulatory:** Uncertainties around NDA submissions and approvals for key products. **Future Operations Impact:** - **Evergreen Acquisition:** Enhances manufacturing and pipeline. - **Life Molecular Acquisition:** Expands Alzheimer's diagnostics. - **SPECT Business Sale:** Focuses on core radiopharmaceuticals. - **R&D Investments:** Continued focus on new products and clinical trials. **Conclusion:** Lantheus Holdings, Inc. (LNTH) reported mixed Q1 2025 results, with revenue growth but lower net income. The company is strategically investing in acquisitions and R&D to drive future growth, despite facing competitive pressures and regulatory uncertainties.